Anlon Healthcare Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹106 Cr +103.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AH

Anlon Healthcare

Q4 FY26Pharmaceuticals & Biotechnology

Anlon Healthcare Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹51Cr
+4.1% YoY
+41.7% QoQ
Net profit
₹11Cr
−35.3% YoY
+120% QoQ
Margin
30%
−5 pp YoY
−5 pp QoQ

Anlon Healthcare Q4 FY26 key numbers

Revenue
FY28 revenue expected to reach INR 700 to 800 crore, driven by organic expansion and new product commercialization.

As stated in Anlon Healthcare's Q4 FY26 earnings call transcript · published 14 Jun 2026. Reported figures, not investment advice.

Price₹29
Market cap₹1.2K Cr
P/E38.5

The short version

FY27 revenue guidance is between INR 380 to 400 crore with existing customer orders and confirmations. FY27 revenue guidance: INR 380 to 400 crore; FY28 expected revenue: INR 700 to 800 crore.

From Anlon Healthcare's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

  • FY27 revenue guidance is between INR 380 to 400 crore with existing customer orders and confirmations.
  • FY28 revenue expected to reach INR 700 to 800 crore, driven by organic expansion and new product commercialization.
  • Peak revenue from current consolidated capacity (1400-1600 MT) estimated around INR 450 to 500 crore considering price increases.
  • Standalone Anlon Healthcare with expansion aims for INR 400 to 450 crore peak revenue.
  • Capacity utilization expected to increase from current ~62-65% to around 80-85% in FY27 and 50-60% in FY28 for new facilities.
  • Revenue growth supported by launching 7 new APIs in FY27 and filing 3-5 additional DMFs to deepen regulated market penetration.

2 more points from Anlon Healthcare's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anlon Healthcare said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company announced a standalone capex of approximately ₹130 crore, with construction expected to start soon and commercial production targeted by Q1 FY28.
  • Funding for this capex will be around ₹65-70 crore through a term loan, approximately 50-60% of the capex, with the remaining funded from internal accruals and expected working capital inflows over the next 4-6 months.
  • Additional working capital will be required to support growth to ₹400 crore topline and potential acquisitions.

2 more points from Anlon Healthcare's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anlon Healthcare said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Current clear visibility of order book is around INR 280 to 300 crore for the whole year on a consolidated basis.
  • The company expects to add an additional INR 80 to 90 crore business during the year based on product demand.
  • Total expected revenue target for FY27 is between INR 380 to 400 crore.
  • CDMO projects: One molecule is in validation stage with commercial supply expected by Q3 FY27.

2 more points from Anlon Healthcare's call on order book

Create a free account to keep reading this call

Anlon Healthcare — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anlon Healthcare Q4 FY26 results — key figures

Anlon Healthcare Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue5149+4.1%36+41.7%
Operating profit (EBITDA)1517-11.8%12+25%
Operating margin30%35%-5 pp35%-5 pp
Profit before tax1415-6.7%11+27.3%
Net profit (PAT)1117-35.3%5+120%
EPS (₹)0.200.42-52.4%0.10+100%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹106 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anlon Healthcare and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anlon Healthcare Q4 FY26 results?

FY27 revenue guidance is between INR 380 to 400 crore with existing customer orders and confirmations. FY27 revenue guidance: INR 380 to 400 crore; FY28 expected revenue: INR 700 to 800 crore.

What is Anlon Healthcare share price analysis?

Anlon Healthcare currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹1,217 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anlon Healthcare planning capital expenditure?

The company announced a standalone capex of approximately ₹130 crore, with construction expected to start soon and commercial production targeted by Q1 FY28.

Keep Anlon Healthcare on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.